CTOs on the Move

BioTek Instruments

www.biotek.com

 
BioTek Instruments is a worldwide leader in the development of high performance, bioanalytical measurement systems and software. Our representatives worldwide call on a variety of customers including academic, government, and biotech/pharmaceutical. We
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.biotek.com
  • PO BOX 998
    Winooski, VT USA 05404
  • Phone: 802.655.4740

Executives

Name Title Contact Details

Similar Companies

Osel Inc

Osel Inc is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.

InGeneron

Founded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research. Headquartered in Houston, Texas,

Bio-Solutions Corporation

Bio-Solutions Corp, Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure.   The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels.

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.